147 related articles for article (PubMed ID: 6114901)
1. Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.
Long RG; Peters JR; Bloom SR; Brown MR; Vale W; Rivier JE; Grahame-Smith DG
Gut; 1981 Jul; 22(7):549-53. PubMed ID: 6114901
[TBL] [Abstract][Full Text] [Related]
2. Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man.
Barnes AJ; Long RG; Adrian TE; Vale W; Brown MR; Rivier JE; Hanley J; Ghatei MA; Sarson DL; Bloom SR
Clin Sci (Lond); 1981 Nov; 61(5):653-6. PubMed ID: 6116553
[TBL] [Abstract][Full Text] [Related]
3. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin.
Roberts LJ; Bloomgarden ZT; Marney SR; Rabin D; Oates JA
Gastroenterology; 1983 Feb; 84(2):272-5. PubMed ID: 6184258
[TBL] [Abstract][Full Text] [Related]
4. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Eur J Clin Pharmacol; 1989; 36(2):133-7. PubMed ID: 2470592
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
Ruszniewski P; Ducreux M; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Bernades P; Rougier P
Gut; 1996 Aug; 39(2):279-83. PubMed ID: 8977344
[TBL] [Abstract][Full Text] [Related]
6. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog.
Price BA; Jaffe BM; Zinner MJ
Gastroenterology; 1985 Jan; 88(1 Pt 1):80-5. PubMed ID: 2856879
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
[TBL] [Abstract][Full Text] [Related]
8. The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man.
Adrian TE; Barnes AJ; Long RG; O'Shaughnessy DJ; Brown MR; Rivier J; Vale W; Blackburn AM; Bloom SR
J Clin Endocrinol Metab; 1981 Oct; 53(4):675-81. PubMed ID: 6116721
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome.
Davis GR; Camp RC; Raskin P; Krejs GJ
Gastroenterology; 1980 Feb; 78(2):346-9. PubMed ID: 7350058
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin-14 modulates postprandial glucose levels and release of gastrointestinal and pancreatic hormones.
O'Shaughnessy DJ; Long RG; Adrian TE; Christofides ND; Ghatei MA; Sarson DL; Bloom SR
Digestion; 1985; 31(4):234-42. PubMed ID: 2861129
[TBL] [Abstract][Full Text] [Related]
11. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
12. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog.
Vinik AI; Gonin J; England BG; Jackson T; McLeod MK; Cho K
J Clin Endocrinol Metab; 1990 Jun; 70(6):1702-9. PubMed ID: 1693375
[TBL] [Abstract][Full Text] [Related]
13. Circulation of a fragment of haemoglobin alpha-chain during a pentagastrin-induced flush in patients with metastatic carcinoid tumours.
Balks HJ; Thim L; Conlon JM
Clin Endocrinol (Oxf); 1988 Mar; 28(3):261-9. PubMed ID: 3168309
[TBL] [Abstract][Full Text] [Related]
14. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
[TBL] [Abstract][Full Text] [Related]
15. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.
Ahlman H; Dahlström A; Grönstad K; Tisell LE; Oberg K; Zinner MJ; Jaffe BM
Ann Surg; 1985 Jan; 201(1):81-6. PubMed ID: 2578277
[TBL] [Abstract][Full Text] [Related]
16. The effects of antral distension on gastric acid secretion and on gastrointestinal hormones in man.
Schöön IM
Acta Physiol Scand Suppl; 1980; 482():1-33. PubMed ID: 6108677
[No Abstract] [Full Text] [Related]
17. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
18. Effects of somatostatin infusion in four patients with malignant carcinoid syndrome.
Quatrini M; Basilisco G; Conte D; Bozzani A; Bardella MT; Bianchi PA
Am J Gastroenterol; 1983 Mar; 78(3):149-51. PubMed ID: 6187212
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
Roy RC; Carter RF; Wright PD
Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas.
Rehfeld JF
Scand J Gastroenterol Suppl; 1979; 53():33-8. PubMed ID: 225784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
